Why the study?
Although the left atrial maze IV alone has been used to eliminate AF without severe right heart diseases, whether a novel modified left atrial maze IV technique could improve 5-year clinical outcomes remained to be investigated.
Does the modified left atrial maze IV (MLAM-IV) procedure improve freedom from atrial fibrillation compared to the standard LAM-IV procedure in patients undergoing valve surgery?
Does the modified left atrial maze IV (MLAM-IV) procedure improve freedom from atrial fibrillation compared to the standard LAM-IV procedure in patients undergoing valve surgery?
The modified left atrial maze IV procedure offers a simpler ablation process with shorter ventilation times and comparable 5-year freedom from atrial fibrillation compared to the standard LAM-IV procedure.
MLAM-IV may shorten ablation and ventilation times; leaves open whether long-term AF freedom improves over LAM-IV in valve surgery.
BACKGROUND: The left atrial maze IV (LAM-IV) alone has been used to eliminate atrial fibrillation (AF) without severe right heart diseases. However, we felt that it could be improved and developed a modified LAM-IV (MLAM-IV). In this prospective trial, we aimed to investigate 5-year clinical outcomes of AF in patients treated by the novel MLAM-IV technique. METHODS: Between September 2012 and October 2013, 120 patients who underwent valve surgery and bipolar radiofrequency ablation for AF were randomized into the LAM-IV group (n = 60) or MLAM-IV group (n = 60). At postoperative follow-up examinations, data were recorded at 1, 3 and 6 months, and annually thereafter. RESULTS: The mean ablation time and postoperative ventilation time were shorter in the MLAM-IV group than in the LAM-IV group (P < 0.001 and P = 0.03, respectively). At 5 years, the rate of freedom from AF was 69.0% in the MLAM-IV group and 60.0% in the LAM-IV group (hazard ratio 0.71, 95% confidence interval 0.39 to 1.32, P = 0.42). There were no differences with respect to the early operative mortality and major complications, late mortality, and major adverse events. CONCLUSIONS: The MLAM-IV provides a technically simpler ablation process. The MLAM-IV was associated with less ventilation support in the early postoperative period. The long-term efficacy of the MLAM-IV in the treatment of AF is comparable to that of the LAM-IV.
No takes yet. Share an insight, caveat, or question.
Shi et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: